ClinicalTrials.gg

Program

CDR132L

A development code. Also written as “CDR132L (i.v.)” and “CDR132L (s.c.)”.

Its studies are mostly in Heart Failure · Myocardial Infarction, led by Novo Nordisk.

Furthest: phase 2, since Apr 20, 20226 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk63 open or runningphase 2since Apr 20, 2022Jul 23, 2019Dec 31, 2026phase 1 · NCT07656454
  • Named in Novo Nordisk’s own pipeline as CDR132L, phase 2, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2019First study: phase 1 study in Heart FailureFirst studyNCT04045405 · 28 enrolled · United Kingdom
  2. Apr 20, 2022Phase 2 study in Myocardial InfarctionNCT05350969 · 294 enrolled · Czechia, Germany, Greece and more
  3. Jun 29, 2023Phase 2 study in Heart FailureNCT05953831
  4. May 15, 20252 phase 2 studies in Heart FailureNCT06979375, NCT06979362
  5. Jun 14, 2026Phase 1 study in Heart FailureNCT07656454 · 32 planned · Germany

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Heart FailureNCT07656454
  2. May 16, 2027Primary completion: phase 2 study in Heart FailureNCT06979375
  3. Nov 16, 2027Primary completion: phase 2 study in Heart FailureNCT06979362

TargetBeta

“CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132).”study text, read by Claude · the study

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656454Heart Failure · Germany1RecruitingDec 31, 202632
NCT06979362Heart Failure · United States, Canada, Germany and more2RecruitingNov 16, 2027200
NCT06979375Heart Failure · Australia, Czechia, Germany and more2RecruitingMay 16, 2027200
NCT05953831Heart Failure2WithdrawnSep 30, 20250
NCT05350969Myocardial Infarction · Czechia, Germany, Greece and more2CompletedSep 26, 2024294
NCT04045405Heart Failure · United Kingdom1CompletedJan 31, 202028

How it is read

Names in the registry

  • “CDR132L”, 5 entries
  • “CDR132L (i.v.)”, 1 entry
  • “CDR132L (s.c.)”, 1 entry

Codes read as this program: CDR132L.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.